Bristol-Myers Sues Teva To Block Generic Baraclude
New Jersey-based Bristol-Myers said in the suit filed Wednesday in the U.S. District Court for the District of Delaware that Teva and its affiliate must be stopped from making and selling entecavir, a generic of Baraclude.
By filing an abbreviated new drug application, Teva is infringing on U.S. Patent No. 5,206,244, issued in 1993 and entitled “Hydroxymethyl (Methylenecyclopentyl) Purines and Pyrimidines,” the...
To view the full article, register now.